Evaluation of Pegylated Interferon Treatment in Patients with Chronic Hepatitis B Virus

Öz

Aim: The main purpose of the treatment of chronic hepatitis B (CHB) infection is cleansing cccal DNA (covalently closed circular DNA) from hepatocytes and eredication of HbsAg.

Material and Methods:To achieve this currently, immunomodulators (standard interferons and pegylated interferons) and nucleoside (t) id analogues are used in the treatment of chronic HBV. We studied 63 naive patients with chronic hepatitis b. As treatment; PEG-IFN alfa 2b, Tenofovir and Entecavir were used in accordance with the guidelines in accordance with the patient's characteristics in the recommended dose according to kilogram. The total duration of treatment and / or follow-up of all the patients studied was 3 years. 

Results: Of the 47 patients who initially received PEG-IFN alpha 2b therapy, 7 were unresponsive, 13 were considered nux.  In 27 patients HBV DNA negativity continued at the end of 3 years. Oral antiviral therapy was given to 36 patients at baseline and to 20 patients at a later time. HBV DNA negativity of these patients is still ongoing.

Conclusion: When the study results were evaluated, it was concluded that pegylated interferons could still be considered as the first option in the appropriate patient group in chronic hepatitis B.

Anahtar Kelimeler

• hepatitis B treatment,oral antivirals,pegylated interferons

Kronik Hepatit B Hastalarının Tedavi Sonuçlarının Değerlendirilmesi

Öz

Giriş: Kronik Hepatit B (KHB) enfeksiyonunun tedavisinde asıl amaç hepatositlerden cccDNA’nın (covalentlyclosedcircular DNA) temizlenmesi ve HBsAg’nin eradikasyonudur. Bu amaca ulaşmak için kronik HBV’nin tedavisinde günümüzde immünomodülatörler (standart interferonlar ve pegile interferonlar) ve nükleos(t)id analogları kullanılmaktadır.

Gereç ve Yöntem: Çalışmamıza KHB tanısı almış naif 63 hasta alındı. Tedavi olarak; hasta özelliklerine göre rehberlere uygun olarak kilograma göre önerilen dozda PEG-IFN alfa 2b, Tenofovir ve Entekavir kullanıldı. Çalışmaya alınan tüm hastaların toplam tedavi ve/veya takip süresi 3 yılı tamamladı.

Bulgular: Başlangıçta PEG-IFN alfa 2b tedavisi alan 47 hastadan 7’ si yanıtsız, 13’ ü nüx kabul edildi, 27 hastada ise HBV DNA negatifliği 3 yılın sonunda devam etti. Diğer 36 hastaya başlangıçta, 20 hastaya ise sonradan toplam 56 hastaya oral antiviral tedavi verildi. Bu hastaların HBV DNA negatifliği halen devam etmektedir.

Sonuç:Çalışma sonuçları değerlendirildiğinde Kronik hepatit B’de uygun hasta grubunda pegile interferonların hala ilk seçenek olarak değerlendirilebileceği sonucuna varılmıştır.

Anahtar Kelimeler

• Hepatit B tedavisi,oral antiviraller,Pegile interferon

Kaynakça

1. 1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97- 107.
2. 2. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-42.
3. 3. Çakaloğlu Y, Ökten A. Hepatit B: Ulusal uzlaşma toplantı metinleri. İstanbul: İstanbul Medikal Yayıncılık; 2003; s. 1-11.
4. 4. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, et al. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis. 2008;8:167-78.
5. 5. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensusstatement on themanagement of chronichepatitis B: a 2005 update. LiverInt. 2005;25:472-89.
6. 6. II. Viral Hepatit Tanı ve Tedavi Rehberi Kitapçığı; Kasım. 2007.
7. 7. Ural O, Sayan M, Akhan S, et al. Türkiye’de ilk kez saptanan Hepatit B Virus Genotip H Enfeksiyonu Olgusu. Mikrobiyoloji Bul 2013; 47(3): 550-555.
8. 8. Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: The REVEAL-HBV study. Clin Liver Dis. 2007; 11(4): 797-816.

9. 9. Türkiye Kronik Viral Hepatit Tanı ve Tedavi Rehberi. 2015;14-16.
10. 10. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J ViralHepat. 2004;11:97- 107.
11. 11. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-42.
12. 12. Tabak F, Balık İ, Tekeli E. Pegilasyon teknolojisi, B tipi kronik hepatitin güncel tedavisi. Viral Hepatit Ohan Matbaası; 2005. s. 199-231.
13. 13. Yang YF, Zhao W, Xia HM, Zhong YD, Huang P, Wen J. Longterm effi cacy of interferon alpha therapy on hepatitis B viral replication in patients with chronic hepatitis B: A meta-analysis. Antiviral Res. (In Press)
14. 14. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudinealone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206-17
15. 15. Wong DK, Cheung AM, O’Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993;119:312-23.